| Trial ID: | L3889 |
| Source ID: | NCT00574912
|
| Associated Drug: |
Placebo
|
| Title: |
Characteristics of Glargine in Type 2 Diabetics
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT00574912/results
|
| Conditions: |
Type 2 Diabetes
|
| Interventions: |
DRUG: Placebo|DRUG: Insulin Glargine 0.5 u/kg body wt SC|DRUG: Insulin Glargine 1.0 u/kg body wt SC|DRUG: Insulin Glargine 1.5 u/kg body wt SC|DRUG: Insulin Glargine 2.0 u/kg body wt SC
|
| Outcome Measures: |
Primary: Maximum Glucose Infusion Rate, measuring the changes in glucose infusion rate during the 24 hour experimental period., 24 hours |
|
| Sponsor/Collaborators: |
Sponsor: Vanderbilt University Medical Center | Collaborators: Sanofi
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
20
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2007-03
|
| Completion Date: |
2010-01
|
| Results First Posted: |
2015-08-03
|
| Last Update Posted: |
2017-04-17
|
| Locations: |
Vanderbilt University, Nashville, Tennessee, 37232, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00574912
|
